Summary: “2023 could potentially be a landmark year for us. This could be the first psychedelic-assisted therapy approved by a regulatory body,” says Amy Emerson, CEO of MAPS Public Benefit Corporation (MAPS PBC) in The Economist.
Originally appearing here (Archived)